Matt Berman
Principal
Indianapolis, IN, US
Matt Berman is principal in the Indianapolis Health Practice and leads the team that provides Market Access Strategy and Agency of Record Services to life science companies. He joined the firm in 2009.
Experience
Matt has more than 10 years of experience supporting life science companies in market access strategy. Project work includes the following general areas:
- Launch strategy market - access focused
- Access stakeholder engagement strategy
- Market segmentation
- Account director training
- Access platform tactical development:
- Evidence generation | PIE presentations | Payer value propositions | Budget impact tools | Design of novel training programs | Implementation guidance
- Pull through program design and execution
- Internal communication and process design | Field-oriented goal setting | Veeva-enabled dynamic pull through messaging | Omni-channel messaging
- Patient journey mapping
- Access landscape development
- Specialty pharmacy strategy
- Patient support and hub design
- Pricing
- Contracting
Presentations and publications
- Berman, M. & Lain, S. "Diabetes burden on population groups: Research summary." July 2019.
- Berman, M. Lain, S., & Metz, L. "Mitigating out-of-pocket costs for insulin users." May 2019.
- Berman, M. & Jackson. A. "Mitigating out-of-pocket costs for prescription drugs." March 2017.
- Berman, M. "Pull-through capabilities: Communicating effectively with prescribers about cost and coverage." February 2014.
Professional Designations
- MBA
Education
- MBA, Kelley School of Business, Indiana University
Publications
Read their latest work
Article
Applying Six Sigma principles to the Medicare Prescription Payment Plan: 5 patient-centered process improvements to maximize value for older adults
17 February 2026 - by Matt Berman, Rachel Crum, Rhea D'Silva, Corinne Owens, Jon Yalcin
How can healthcare stakeholders use Six Sigma to transform the Medicare Prescription Payment Plan into a widely adopted and trusted benefit?
Article
Navigating national priority vouchers: Three critical shifts affecting strategy for life sciences companies and payers
03 December 2025 - by Matt Berman, Chris Page, Chad Barker, Corinne Owens
We discuss three critical shifts for life sciences companies to consider in the wake of the FDA’s new structure for approval timelines for selected products.
Article
Beneficiary considerations for the Medicare Prescription Payment Plan
18 November 2024 - by Matt Berman, Adam Feller, Chad Barker, Jacob Hahn
We explore the Medicare Prescription Payment Plan's benefits and challenges for beneficiaries, emphasizing the need for clear communication and education to enhance understanding and decision-making.
Article
FTC pharmacy benefit management transparency report: How might pharma evaluate transparency reform impacts to drug channel stakeholders?
04 September 2024 - by Chad Barker, Chris Page, Matt Berman
In the wake of the FTC’s recent transparency report on pharmacy benefit managers, we look at how reform might impact drug channel stakeholders.
Article
The Inflation Reduction Act passed, now what?
30 September 2022 - by AJ Ally, Matt Berman, Michelle (Klein) Robb, Kevin Pierce
Drug manufacturers should take the time now to understand how the Inflation Reduction Act will affect Medicare and carefully plan.
Article
Insulin legislative changes: Current proposals and road map
13 July 2022 - by Matt Berman, Kevin Pierce
We examine various Congressional proposals that would affect insulin, including potential impacts on stakeholders and downstream health equity implications.
Article
Potential policy changes that could upend prescription drug pricing
16 April 2022 - by AJ Ally, Matt Berman
We discuss three primary targets to reduce prescription drug costs in the U.S., with potentially substantial changes in pricing for Medicare Parts B and D.
Article
Diabetes burden on population groups: Research summary
22 July 2019 - by Matt Berman, Scott Lain
This report provides data on the burden of diabetes on various subsets of the U.S. population.
Article
Mitigating out-of-pocket costs for insulin users
30 May 2019 - by Matt Berman, Scott Lain, Luke Metz
This report identifies potential approaches that plan administrators could take in an effort to reduce out-of-pocket costs for insulin-taking members.
Article
Mitigating out-of-pocket costs for prescription drugs
27 March 2017 - by Matt Berman, Elizabeth Anne Jackson
This analysis identifies tactics plan administrators could adopt that would reduce out-of-pocket costs for brand-name drugs.